Voyager Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 9, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 9, 2026

VYGR$1.83-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive (Loss)

**Consolidated Statements of Operations and Comprehensive (Loss)**Income

(amounts in thousands, except share and per share data)


· · Year ended ·
· · December 31,
· · 2025 · · 2024 · · 2023
Collaboration revenue	$40,374	$80,001	$250,008
Operating expenses:
Research and development	134,674	127,368	92,172
General and administrative	37,544	35,920	35,822
Total operating expenses	172,218	163,288	127,994
Operating (loss) income	(131,844)	(83,287)	122,014
Other income, net:
Interest income	10,618	18,328	11,721
Other income	1,649	622	3
Total other income, net	12,267	18,950	11,724
(Loss) income before income taxes	(119,577)	(64,337)	133,738
Income tax provision	144	665	1,408
Net (loss) income	$(119,721)	$(65,002)	$132,330
Other comprehensive income (loss)
Net unrealized gain (loss) on available-for-sale-securities	439	(359)	171
Total other comprehensive income (loss)	439	(359)	171
Comprehensive income (loss)	$(119,282)	$(65,361)	$132,501

Net (loss) income per share, basic	$(2.04)	$(1.13)	$3.08
Net (loss) income per share, diluted	$(2.04)	$(1.13)	$2.97

Weighted-average common shares outstanding, basic	58,691,136	57,667,543	43,020,747
Weighted-average common shares outstanding, diluted	58,691,136	57,667,543	44,569,334

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.